Hookipa Pharma (NASDAQ:HOOK) Rating Reiterated by SVB Leerink

Hookipa Pharma (NASDAQ:HOOK)‘s stock had its “buy” rating restated by SVB Leerink in a report issued on Sunday, Price Targets.com reports.

A number of other research analysts have also commented on the company. Morgan Stanley cut their target price on Hookipa Pharma from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Wednesday, August 18th. Zacks Investment Research cut shares of Hookipa Pharma from a “buy” rating to a “hold” rating in a research note on Friday, July 23rd. TheStreet downgraded shares of Hookipa Pharma from a “c-” rating to a “d” rating in a report on Wednesday, July 7th. Finally, JMP Securities reissued a “buy” rating and issued a $25.00 target price on shares of Hookipa Pharma in a research note on Friday, June 4th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Hookipa Pharma has an average rating of “Buy” and an average target price of $20.43.

NASDAQ:HOOK opened at $6.55 on Friday. The firm’s 50-day moving average is $7.15 and its 200-day moving average is $10.89. The company has a market cap of $170.78 million, a price-to-earnings ratio of -3.21 and a beta of 1.11. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.23 and a current ratio of 4.23. Hookipa Pharma has a 52-week low of $6.01 and a 52-week high of $20.00.

Hookipa Pharma (NASDAQ:HOOK) last released its earnings results on Thursday, August 12th. The company reported ($0.52) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.52). Hookipa Pharma had a negative return on equity of 47.02% and a negative net margin of 304.07%. Equities analysts predict that Hookipa Pharma will post -2.13 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Morgan Stanley increased its position in shares of Hookipa Pharma by 3,639.8% during the 2nd quarter. Morgan Stanley now owns 149,256 shares of the company’s stock worth $1,367,000 after purchasing an additional 145,265 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Hookipa Pharma by 306.9% during the second quarter. Wells Fargo & Company MN now owns 65,257 shares of the company’s stock worth $597,000 after buying an additional 49,221 shares in the last quarter. Woodline Partners LP raised its stake in shares of Hookipa Pharma by 32.5% in the second quarter. Woodline Partners LP now owns 901,602 shares of the company’s stock valued at $8,259,000 after acquiring an additional 221,342 shares during the last quarter. Millennium Management LLC bought a new position in shares of Hookipa Pharma in the second quarter valued at approximately $3,553,000. Finally, UBS Asset Management Americas Inc. acquired a new position in shares of Hookipa Pharma in the 2nd quarter worth approximately $3,034,000. 47.97% of the stock is currently owned by institutional investors and hedge funds.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

Recommended Story: How to calculate the annual rate of depreciation

Analyst Recommendations for Hookipa Pharma (NASDAQ:HOOK)

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.